It also said that J&J has reached an agreement with one of the lawyers resisting a deal, Allen Smith, who along with another firm represents around 12,000 plaintiffs out of several tens of ...

Once-daily oral IL-23 inhibitor icotrokinra (formerly JNJ-2113) – which J&J licensed from Protagonist Therapeutics in 2017 – hit both its main efficacy objectives in the ICONIC-LEAD trial ...

Last year, the model accurately predicted that Texans quarterback C.J. Stroud might take a step back in his second season. He finished as QB18 and anybody who avoided drafting him early dodged a ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.